Published :
Tables : 46
Figures : 43
Category : Healthcare
No. of Pages : 216
Report Code : HC-1327
Depression Drugs Market is estimated to value over CAGR of over 1.8% during the forecast period 2022 to 2028. Antidepressants or depression drugs refer to the broad range of medications that are consumed by patients for the treatment of mental disorders such as depression and social anxiety. They are especially formulated to balance the functioning of neurotransmitters such as controlling the emotions and mood of the patient and serotonin in the brain. Depression and other mental ailments are best described as the mental state that is devoid of positive emotions, mood swings and a number of physical, cognitive, emotional and behavioral symptoms. Depression drugs can help in providing relief in the symptoms of seasonal affective disorder, anxiety and dysthymia. Certain antidepressant drugs include the use of Monoamine Oxidase Inhibitors (MAOIs), Selective Serotonin Reuptake Inhibitors (SSRIs) and atypical antidepressants. These drugs produce good results when consumed along with regular therapeutic sessions. Market study demonstrates that there is a growing pattern in depression-related disorders on a global scale and that such patterns have been registered to drive augment the market growth in the forecast time frame. Depression in adults and adolescents alike, have seen a rise owing to several reasons such as inadequate dietary food habits, social alienation and work life imbalance. Moreover, the growing geriatric population on a global scale, is afflicted with social isolation from friends and family alike, as well as other health related issues. All these factors combined, have anticipated an expansion in the depression drugs market size in the forecast period. However, it is to be observed, that there is growing awareness about depression as a psychological illness and the methods and strategies which are undertaken to cure it, which has led to the increased adoption of these drugs in patients belonging to all groups. In addition, the prevalence of novel techniques for the cultivation of antidepressants with the least number of side effects with prolonged positive results as well as an adoption and positive outlook on these medications has been expected to heighten the market growth in the forecast timeline. For example, psychedelics like ketamine are extensively viewed as beneficial easing the symptoms of depression and offering a remedy. The depressive disorder segment is bifurcated into panic disorder, major depressive disorder, generalized anxiety disorder, obsessive compulsive disorder and others. Major depressive disorder emerges as the primary factor behind the market growth as a number of people are afflicted with this disorder owing to a rise in the levels of stress. Having said that, obsessive compulsive disorder is among the most rapidly growing segment. The market is fragmented into serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors etc. Among this segment, it is the serotonin-norepinephrine reuptake inhibitors that has brought the largest revenue. Prominent players in the Market includes: Allergan, Plc, Novartis International AG, Lupin Pharmaceuticals, Inc., Abbott Laboratories and Janssen Pharmaceuticals, Inc., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, GlaxoSmithKline, Pfizer. Depression Drugs Market Segmentation: By Depressive Disorder Major Depressive Disorder Obsessive-Compulsive Disorder Generalized Anxiety Disorder Panic Disorder Others By Product Tricyclic Antidepressants Selective Serotonin Reuptake Inhibitors Serotonin- Norepinephrine Reuptake Inhibitors Monoamine Oxidase Inhibitors Serotonin Antagonist & Reuptake Inhibitors Others By Distribution Channel Retail Pharmacies Hospital Pharmacies Online Pharmacies By Region North America Europe Asia Pacific Latin America Middle East & Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global depression drugs market by depressive disorder, by product, by distribution channel and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Antidepressants or depression drugs refer to the broad range of medications that are consumed by patients for the treatment of mental disorders such as depression and social anxiety. They are especially formulated to balance the functioning of neurotransmitters such as controlling the emotions and mood of the patient and serotonin in the brain. Depression and other mental ailments are best described as the mental state that is devoid of positive emotions, mood swings and a number of physical, cognitive, emotional and behavioral symptoms. Depression drugs can help in providing relief in the symptoms of seasonal affective disorder, anxiety and dysthymia. Certain antidepressant drugs include the use of Monoamine Oxidase Inhibitors (MAOIs), Selective Serotonin Reuptake Inhibitors (SSRIs) and atypical antidepressants. These drugs produce good results when consumed along with regular therapeutic sessions.
Market study demonstrates that there is a growing pattern in depression-related disorders on a global scale and that such patterns have been registered to drive augment the market growth in the forecast time frame. Depression in adults and adolescents alike, have seen a rise owing to several reasons such as inadequate dietary food habits, social alienation and work life imbalance. Moreover, the growing geriatric population on a global scale, is afflicted with social isolation from friends and family alike, as well as other health related issues. All these factors combined, have anticipated an expansion in the depression drugs market size in the forecast period. However, it is to be observed, that there is growing awareness about depression as a psychological illness and the methods and strategies which are undertaken to cure it, which has led to the increased adoption of these drugs in patients belonging to all groups.
In addition, the prevalence of novel techniques for the cultivation of antidepressants with the least number of side effects with prolonged positive results as well as an adoption and positive outlook on these medications has been expected to heighten the market growth in the forecast timeline. For example, psychedelics like ketamine are extensively viewed as beneficial easing the symptoms of depression and offering a remedy.
The depressive disorder segment is bifurcated into panic disorder, major depressive disorder, generalized anxiety disorder, obsessive compulsive disorder and others. Major depressive disorder emerges as the primary factor behind the market growth as a number of people are afflicted with this disorder owing to a rise in the levels of stress. Having said that, obsessive compulsive disorder is among the most rapidly growing segment.
The market is fragmented into serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors etc. Among this segment, it is the serotonin-norepinephrine reuptake inhibitors that has brought the largest revenue.
Prominent players in the Market includes:
Allergan, Plc, Novartis International AG, Lupin Pharmaceuticals, Inc., Abbott Laboratories and Janssen Pharmaceuticals, Inc., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, GlaxoSmithKline, Pfizer.
Depression Drugs Market Segmentation:
By Depressive Disorder
By Product
By Distribution Channel
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Depression Drugs Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Depression Drugs Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Depression Drugs Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Depression Drugs Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Depression Drugs Market, By Depressive Disorder Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Major Depressive Disorder 7.2. Obsessive-Compulsive Disorder 7.3. Generalized Anxiety Disorder 7.4. Panic Disorder 7.5. Others 8. Global Depression Drugs Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Tricyclic Antidepressants 8.2. Selective Serotonin Reuptake Inhibitors 8.3. Serotonin- Norepinephrine Reuptake Inhibitors 8.4. Monoamine Oxidase Inhibitors 8.5. Serotonin Antagonist & Reuptake Inhibitors 8.6. Others 9. Global Depression Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Retail Pharmacies 9.2. Hospital Pharmacies 9.3. Online Pharmacies 10. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. U.S.A 10.2.2. Canada 10.2.3. Mexico 10.3. Market Size (USD Million) Forecast for North America 2022-2028 11. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Brazil 11.2.2. Venezuela 11.2.3. Argentina 11.2.4. Rest of Latin America 11.3. Market Size (USD Million) Forecast for Latin America 2022-2028 12. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Germany 12.2.2. U.K 12.2.3. France 12.2.4. Italy 12.2.5. Spain 12.2.6. Russia 12.2.7. Poland 12.2.8. Rest of Europe 12.3. Market Size (USD Million) Forecast for Europe 2022-2028 13. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Japan 13.2.2. China 13.2.3. India 13.2.4. Australia and New Zealand 13.2.5. ASEAN 13.2.6. Rest of Asia Pacific 13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 14. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. GCC 14.2.2. Israel 14.2.3. South Africa 14.2.4. Rest of MEA 14.3. Market Size (USD Million) Forecast for MEA 2022-2028 15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 15.1. Allergan, Plc 15.1.1. Company Overview 15.1.2. Product Portfolio 15.1.3. SWOT Analysis 15.1.4. Financial Overview 15.1.5. Strategic Overview 15.2. Novartis International AG 15.2.1. Company Overview 15.2.2. Product Portfolio 15.2.3. SWOT Analysis 15.2.4. Financial Overview 15.2.5. Strategic Overview 15.3. Lupin Pharmaceuticals, Inc. 15.3.1. Company Overview 15.3.2. Product Portfolio 15.3.3. SWOT Analysis 15.3.4. Financial Overview 15.3.5. Strategic Overview 15.4. Abbott Laboratories 15.4.1. Company Overview 15.4.2. Product Portfolio 15.4.3. SWOT Analysis 15.4.4. Financial Overview 15.4.5. Strategic Overview 15.5. Janssen Pharmaceuticals, Inc. 15.5.1. Company Overview 15.5.2. Product Portfolio 15.5.3. SWOT Analysis 15.5.4. Financial Overview 15.5.5. Strategic Overview 15.6. Johnson & Johnson 15.6.1. Company Overview 15.6.2. Product Portfolio 15.6.3. SWOT Analysis 15.6.4. Financial Overview 15.6.5. Strategic Overview 15.7. Otsuka Pharmaceutical Co., Ltd. 15.7.1. Company Overview 15.7.2. Product Portfolio 15.7.3. SWOT Analysis 15.7.4. Financial Overview 15.7.5. Strategic Overview 15.8. Eli Lilly and Company 15.8.1. Company Overview 15.8.2. Product Portfolio 15.8.3. SWOT Analysis 15.8.4. Financial Overview 15.8.5. Strategic Overview 15.9. Takeda Pharmaceutical Company Limited 15.9.1. Company Overview 15.9.2. Product Portfolio 15.9.3. SWOT Analysis 15.9.4. Financial Overview 15.9.5. Strategic Overview 15.10. GlaxoSmithKline 15.10.1. Company Overview 15.10.2. Product Portfolio 15.10.3. SWOT Analysis 15.10.4. Financial Overview 15.10.5. Strategic Overview 15.11. Pfizer 15.11.1. Company Overview 15.11.2. Product Portfolio 15.11.3. SWOT Analysis 15.11.4. Financial Overview 15.11.5. Strategic Overview 16. Pre and Post COVID-19 Impact 16.1. Positive influence on the healthcare industry 16.2. The financial disruption of the manufacturing sector 16.3. Impact of COVID-19 on emerging companies 16.4. Significant mandates in the healthcare regulations initiated by administrations 16.5. The overall economic slowdown of the developing and developed nations 17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics